Atara Biotherapeutics (ATRA) Cash from Financing Activities (2013 - 2026)

Atara Biotherapeutics' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 1280.4% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.3 million (down 44.69% YoY) and the FY2025 annual result came in at $16.1 million, down 72.85% from the prior year.
• Cash from Financing Activities was $3.0 million for Q1 2026 at Atara Biotherapeutics, up from -$3000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $35.8 million in Q3 2024 and bottomed at -$328000.0 in Q4 2024.
• A 5-year average of $7.8 million and a median of $1.0 million in 2025 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 17308.17% in 2024, while the deepest fall reached 168.79% in 2024.
• Atara Biotherapeutics' Cash from Financing Activities stood at $32.3 million in 2022, then plunged by 95.32% to $1.5 million in 2023, then tumbled by 121.69% to -$328000.0 in 2024, then surged by 99.09% to -$3000.0 in 2025, then surged by 98466.67% to $3.0 million in 2026.
• Business Quant data shows ATRA's Cash from Financing Activities at $3.0 million in Q1 2026, -$3000.0 in Q4 2025, and $1.0 million in Q3 2025.